. Identification of liver protein targets modified by tienilic acid metabolites using a two-dimensional Western blot-mass spectrometry approach.
Introduction
Drug induced autoimmune hepatitis, characterized by hepatitic, cholestatic, or miscellaneous clinical features belongs to some of the most severe adverse drug reactions. Common to these reactions are the involvement of an improper immune response that is directed toward the host's liver. Studies in the past indicate that the uricosuric diuretic agent, tienilic acid (also named, Ticrynafen, Selacryn, Diflurex; 2,3-dichloro-4-(2-thienylcarbonyl) phenoxyacetic acid) (TA) causes drug inducedautoimmune hepatitis in certain persons. As a consequence, TA was withdrawn from clinical use in the United States in the early eighties [1] and in France in 1992. Although several mechanisms may be involved, the current understanding of drug inducedautoimmune diseases is based on two interdependent complementary working hypotheses e.g. the "Hapten" and the "Danger" hypothesis [2] [3] [4] . Of importance for both hypotheses is the requirement for metabolic transformation of the drug to a reactive metabolite(s), resulting in two different but essential outcomes. The first involves covalent modification of cellular macromolecules by reactive metabolites that after intra cellular processing lead to modified peptides being presented as antigens to the immune system, probably via the MHC processing system. In addition, it seems likely that in order to trigger the immune response some kind of cellular stress should be present. This assumption is based on the fact that immune mediated adverse drug reactions are dramatically increased in persons concomitantly infected with a virus or suffering from other ailments [5] .
Metabolic activation of a drug causing either direct or indirect up-regulation of cellular stress proteins could be involved. Alternatively, modification of essential or specific stress proteins could be an important factor resulting in cellular stress. Initial phases of 4 TA toxicity are believed to be due to metabolic activation by CYP450 2C9 to a reactive metabolite that can deplete glutathione (GSH) and covalently bind to certain proteins. Analysis of sera obtained from patients suffering from liver damage following TA exposure revealed the presence of highly specific anti-liver and kidney microsomal (anti-LKM2) autoantibodies [6] known to specifically recognize CYP450 2C9 in humans [7, 8] and the corresponding isoform 2C11 in rats [9] . Subsequent studies have revealed that tienilic acid undergoes a selective CYP450 2C9-mediated bioactivation on its thiophene ring, resulting in the formation of a reactive intermediate that covalently modifies the enzyme [10] despite that a stable peptide conjugate has never characterized [11, 12] . A relatively limited number of proteins appear to be modified by TA metabolites in both human and rat liver microsomes [9, 10, 13, 14] . In contrast, the isomer of TA has been shown to be metabolized into a thiophene sulfoxide, leading to modification of many more proteins [9, 15, 16] . In addition, TA could be metabolized by other until now unknown or known enzymes without suicide inactivation resulting in protein modification but this has yet to be confirmed. For a number of carboxylic acid containing drugs, glucuronidation has been proposed to be a major metabolic pathway that potentially could increase the reactivity of certain drugs resulting in covalent modification of proteins [17] . The formation of reactive metabolites by this pathway and covalent protein modification has previously been demonstrated for numerous non steroidal anti-inflammatory drugs including ibuprofen [18] , ketoprofen [19] and zomepirac [20] as well as for other drugs like mycophenolic acid [21] , clofibric acid [20] , diflunisal [22, 23] and valproic acid [20] . Despite that proteins have been found to be covalently modified by reactive drug metabolites both in vivo and in vitro, only a 5 relatively small number have until know been identified. So far, proteomics approaches based on mass spectrometry and separation techniques suitable for this type of analysis, have only been used in a few cases [21, 24, 25] . Recently, we developed a new approach allowing the mass spectrometric analysis of immuno-reactive protein spots obtained from the membrane used for Western blotting and thus to identify post translationally modified proteins including those modified by reactive drug metabolites [26] . Except for CYP P450 2C9 and the 2C11 variant in rats, a comprehensive knowledge about what cellular proteins are covalently modified after exposure to TA is still lacking. The aim of the present study was to take advantage of a proteome approach exploiting pre-fractionation of cellular organelles and 2D Western blotting in combination with mass spectrometry to identify the comprehensive suite of modified rat liver proteins.
Experimental

Animals and sample preparation
The experimental protocol was approved by the institution animal care unit. Wistar rats (~200-250 g) were allowed to rest for one week before exposure to TA. Rats having received an injection intra-peritoneal of TA (100 mg of drug per kg of weight) or saline (control) were sacrificed at 4 and 24 hours respectively. The livers were immediately removed, sliced into small pieces with a clean scalpel and homogenized at 4ϒC in 7 ml of buffer (10mM Tris-HCl pH 7.5, 250 mM sucrose, 20 µl peptidase inhibitor cocktail) using a potter helm homogenizer with a loose pestle and 5-10 strokes per 1g of liver.
These procedures were repeated in two independent experiments.
2.2 Enrichment of liver sub-cellular fractions by ultra-centrifugation.
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Rat liver homogenate was centrifuged at 600 x g for 10 min to precipitate cell nuclei and cellular debris. The supernatant was collected, transferred into ultracentrifuge tubes and further centrifuged at 15.000 x g for 5 min. The precipitate represented fraction I. Centrifugation of the supernatant at 100.000 x g for 60 min resulted in fraction II. The last ultracentrifugation at 100.000 x g for 5 hours gave fraction III (precipitate) and fraction IV (supernatant). Centrifugations were performed at 4 ϒC using a Sorvall RC 5B plus centrifuge (Mandel, ON, Canada) and the enriched sub-cellular fractions were stored at -20ϒC until further analysis. Protein concentrations in each step were estimated using the BCA assay (Pierce, Rockford, IL, US). Samples were dissolved in 10% SDS and dilutions were made in 1% SDS prior to performing the assay as described by the manufacture. The flow rate was split approximately 10x to 0.25-0.30 µl/min. Survey scans were acquired at 1.9 s/scan. Depending on the charge state and intensity, doubly and triply charged parent ions were automatically selected for tandem mass spectrometry acquired at 1 s/scan with a pre-set maximum of 5 scans per selected parent ion. Since singly charged parent ions were not selected for tandem mass spectrometry, the intensity threshold could be lowered to a minimum without the risk of spending acquisition time on ions from background, impurities and detergents. Although a low threshold is not a guaranty of acquiring MS/MS spectra useful for protein identification, it ensure selection of a maximum number of doubly and triply charged ions for MS/MS analysis, during the separation. Raw MS/MS spectra were processed automatically using the ProteinLynx software and converted into peak lists readable by the MASCOT search algorithm (http://www.matrixscience.com). The following search parameters were used: database; MSDB, species; Rattus, allowance of two missed tryptic cleavages, oxidation of methionine and cysteine carbamidomethylation, fragment mass tolerance; 0.25 Da.
Results
To achieve a survey and identify the suite of rat liver proteins modified by TA metabolites, rats were treated with either saline (control) or TA (100 mg/kg). After time intervals of 4 and 24 hours, the liver was isolated, homogenized and proteins were separated by 2D SDS PAGE. In preliminary experiments, proteins from total liver homogenates were focused in the first dimension from pH 3-10 followed by separation in the second dimension on gradient polyacrylamide gels. Proteins modified covalently by TA metabolites were visualized on the corresponding Western blots with a polyclonal antiserum to TA [9] . A maximum of approximately 20 spots appeared to contain modified proteins, as judged by their immuno-reactivity. The spots were absent on Western blots of the control and appeared to increase in number from 4 to 24 h in two independent experiments. Although, it could not be entirely excluded that the increased intensity are due to variations in the sample amounts loaded onto the gels, the absence of immuno reactive spots in the control lead us to conclude that the immuno-reactivity was not due to non-specific cross reactivity of the antiserum ( Figure 1 ). As the ECL images were very similar but the number of immuno-reactive spots was increased at 24 h, we decided to pursue the subsequent analyses using the liver recovered from this rat. All of the immuno-reactive spots were estimated to be within the isoelectric point range 5-7.
This was further confirmed by 2D Western blotting of total liver homogenate after isoelectric focusing on 4-7 IPG strips (data not shown). Preliminary attempts to identify the modified proteins using on-membrane digestion, nLC-ESIMS/MS and data base searching turned out to be complicated by the fact that the protein spots were highly heterogeneous because of incomplete protein separation (data not shown). Therefore, to improve the electrophoretic separation of the proteins and to increase the likelihood of detecting most proteins potentially adducted with TA, we took advantage of two sample purification steps. Firstly, total liver homogenates were subjected to rough pre-fractioning with ultra-centrifugation. This step resulted in four major fractions (I-IV). Secondly, the proteins were separated in the first dimension using IPG strips with a narrow pH range.
An overview of the strategy used throughout this work is shown in figure 2 . The four fractions, obtained after ultracentrifugation were subjected to isoelectric focusing using together with adenosylhomocysteinase it may be a candidate for the immuno-reactivity.
Although it cannot be excluded, it is uncertain as to whether beta-alanine synthethase and 4-hydroxyphenylpyruvate dioxygenase are candidates because they constantly comigrated with other highly potential immuno-reactive candidates (Table I, spot 9 and 10,   Table II, spot 17, Table IV spot 11 and 12 ). Interpretation of collective data from the analyses of four fractions using the procedure described above resulted in a list of 15 candidate proteins shown in Table V that are likely to be modified by TA metabolites.
Although rat albumin was found in most of the fractions and was identified in several of the spots, these analyses did not allow us to unambiguously conclude that rat albumin is modified by TA metabolites because the antiserum was raised against bovine albumin-TA conjugates. However, the absence of spots corresponding to rat albumin on control
Western blots indicates that, if present, cross reactivity is limited. Furthermore, keratins can easily contaminate carrier protein drug metabolite preparations. In both cases, antigen cross reactivity could not be completely eliminated, and thus these proteins were not included in table V.
Discussion
In the present work, we demonstrate that 2D Western blotting in direct conjunction with nLC-MS/MS can be used to identify rat liver proteins that are highly likely to be covalently modified by TA metabolites. Previously, the identification of proteins modified by drug metabolites using Western blotting was limited to in gel digestion of the proteins of interest after localisation of the spots on a 2D SDS PAGE gel using an ECL image obtained from immuno-blotting of a parallel gel. This method is useful when immuno-reactive proteins can be observed with mass spectrometry compatible gel staining methods. However, in our hands, this is not always the case rendering the location of the immuno-reactive spots very difficult due to the extensive discrepancy of ECL and gel staining images. In contrast, our method takes advantage of the fact that after on-membrane proteolysis it is possible to recover sufficient amount of peptides from the India ink stained PVDF membrane used for immuno-blotting to subsequently acquire high quality nLC-MS/MS data. Furthermore, the facility and precision by which the protein spots can be located on the PVDF membrane after superposition of the ECL image insure that the correct immuno-reactive spot is excised and the method is therefore likely to diminish faulty protein identifications. Considering the frequently high sensitivity of immuno-blotting one can not exclude that, from a mass spectrometry point of view, undetectable lower levels of immuno-reactive proteins could be present. The sensitivity of the method depends on the mass spectrometer used for analyses. With the instrument used in this study, the lower limit of detection was estimated from injecting a standard peptide mixture to be about 25-50 femtomol per peptide in order to obtain adequate tandem mass spectra for protein identification. Of notice, the protein amount retained on the PVDF membrane of several immuno-reactive protein spots was insufficient for visualization by India ink staining. Although this compromised the choice of an appropriate spot size to excise, the dimension of our spot picking tool corresponded well to the vast majority of spots observed on the ECL transparency. Nevertheless, it can obviously not be excluded that some of the protein heterogeneity could be due to excision of closely located neighbouring proteins. Despite that relatively few immuno-reactive spots were homogenous, the occurrence of protein isomers in several spots from identical fractions and their co-migration with different proteins in other fractions aided in determining which proteins may be responsible for the immuno-reactivity observed by ECL. Optimal separation can be obtained with longer immobiline strips and larger 2D gels, however, at the expense of a larger consumption of antibodies and ECL reagents.
Furthermore, larger gels are in general more fragile and difficult to handle for the purpose of immuno blotting. In light of these considerations, we chose to use a medium size gel (10 x 10 cm) compromising to some extend the protein separation. Attempts to determine which peptides, site and type of covalent modification(s) using the GPM search engine (http://rat.thegpm.org/tandem/thegpm_tandem.html) and calculated molecular weights of possible metabolites were unsuccessful. This is not surprising because only a minor fraction of a target protein is probably modified [27] [28] [29] . Thus, even if present, the amount of a modified peptide may be lower than the instrumental limit of detection. If the modification is fragile, it could undergo fragmentation in the electrospray-ms interface, resulting in loss of further structural analysis. However, this is unlikely as covalent conjugates of both gluthathione-TA and mercaptoethanol-TA isomer metabolites were successfully analysed by ESI-MS in earlier studies [12, 16] . Nevertheless, it cannot be excluded that modified peptides could be labile in the LC solvent resulting in loss of adducts during separation, as proposed previously [11] . In summary, 15 proteins were found to be covalently modified. Surprisingly, Cytochrome P450 2C11 was not identified despite that the protein was previously reported to be modified by a reactive intermediary of TA [13] . In this study, densiometric quantification of immuno blots showed maximum modification to occur in rats 2-4 h after TA ingestion, followed by a steady decline until 36 h. The level of modification was approximately 20% of total after exposure for 24 h, the delay time we used, before isolating the liver for 2D Western blotting and protein identification. In addition, the conditions for immuno blotting were different because we did not use any protein blocking reagents. Finally, we separated the proteins by 2D electrophoresis using a method not especially optimized for membrane proteins, and since CYP 2C11 likely is a membrane bound protein and therefore notoriously more difficult to handle, it may well have escaped detection. Three proteins identified, which include selenium binding protein, disulfide isomerase and Hsc73, have been shown to be common targets for other reactive drug intermediates and chemicals in previous studies.
Selenium binding protein 2 was previously found to be covalently modified by the reactive intermediary N-acetyl-p-benzoquinone, a metabolite of acetaminophen [30, 31] , metabolites of chemicals like 3'-hydroxyacetanilide [32] and bromobenzene [33] . The function of selenium binding protein is presently unknown but it has been suggested to function as a scavenger protein involved in the cellular defence mechanism [31] . In contrast, the protein was recently shown to increase acetaminophen toxicity when over expressed in COS-1 cells, and thus, this subject is still controversial [34] . Because disulphide isomerase is an abundant protein involved in redox state control it is critical for maintaining apt cellular homeostasis. This protein catalyzes the rearrangement of disulphide bonds. Thus, the toxicological consequence(s) of a reactive TA intermediary may depend on the extent of modification and potential malfunction of disulphide isomerase. Similarly, this protein seems to be a common target for various reactive intermediaries including mycophenolic acid [21] , naphthalene [25] , halothane [35] , bromobenzene [36] , monocrotaline [37] . The dnaK-type molecular chaperone Hsc73, also called Hsc70 or Hspa8, was previously shown to be adducted by a reactive intermediary of naphthalene [25] . 
